Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study

[1] Jennette JC(2013)2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides Arthritis Rheum. 65 1-11

[2] Falk RJ(2013)Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention Am J Kidney Dis. 62 1176-87

[3] Bacon PA(2007)Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis J Am Soc Nephrol. 18 2180-8

[4] Kallenberg CG(2009)EULAR recommendations for the management of primary small and medium vessel vasculitis Ann Rheum Dis. 68 310-7

[5] Stegeman CA(2013)Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear Kidney Int. 84 397-402

[6] Abdulahad WH(2013)Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial Trials. 14 73-7

[7] Jayne DR(2007)Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies Ann Rheum Dis. 66 222-8

[8] Gaskin G(2001)Development and validation of a Disease Extent Index for Wegener’s granulomatosis Clin Nephrol. 55 31-60

[9] Rasmussen N(2012)Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up Ann Rheum Dis. 71 955-24

[10] Mukhtyar C(2013)Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis Clin J Am Soc Nephrol. 8 219-4

[1] Jennette JC(2013)2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides Arthritis Rheum. 65 1-11

[2] Falk RJ(2013)Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention Am J Kidney Dis. 62 1176-87

[3] Bacon PA(2007)Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis J Am Soc Nephrol. 18 2180-8

[4] Kallenberg CG(2009)EULAR recommendations for the management of primary small and medium vessel vasculitis Ann Rheum Dis. 68 310-7

[5] Stegeman CA(2013)Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear Kidney Int. 84 397-402

[6] Abdulahad WH(2013)Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial Trials. 14 73-7

[7] Jayne DR(2007)Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies Ann Rheum Dis. 66 222-8

[8] Gaskin G(2001)Development and validation of a Disease Extent Index for Wegener’s granulomatosis Clin Nephrol. 55 31-60

[9] Rasmussen N(2012)Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up Ann Rheum Dis. 71 955-24

[10] Mukhtyar C(2013)Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis Clin J Am Soc Nephrol. 8 219-4